The Transplant Solutions Company •F E B R U A R Y 2 6 , 2 0 2 5 Click to edit Master text styles Click to edit Master title style Patrick G, Kidney Transplant Recipient Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, i ...

CareDx, Inc (NASDAQ:CDNA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Bill Bonello - Craig-Hallum Andrew Cooper - Raymond James Mason Carrico - Stephens Eduardo Martinez - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good afternoon, everyone. Welcome to the CareDx, Inc. Fourth Qua ...

CareDx (CDNA) Q4 2024 Earnings Call February 27, 2025 08:49 AM ET Company Participants Caroline Corner - Vice President of Finance and Investor RelationsJohn Hanna - President and CEOAbhishek Jain - CFOPrashant Kota - Equity Research AssociateAndrew Cooper - VP - Equity ResearchEduardo Martinez-Montes - Biotechnology Equity Research AssociateThomas DeBourcy - Principal Conference Call Participants None - AnalystMark Massaro - Managing Director - Senior Equity Research AnalystWilliam Bonello - Senior Researc ...

Core Insights - CareDx reported $86.58 million in revenue for Q4 2024, a 32% year-over-year increase, with an EPS of $0.18 compared to -$0.17 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $85.5 million by 1.26%, and the EPS surpassed the consensus estimate of $0.07 by 157.14% [1] Revenue Breakdown - Revenue from Patient and Digital Solutions was $11.39 million, exceeding the average estimate of $10.99 million by analysts, representing an 18.4% year-over-year increase [4] - Revenue from Testing Services reached $63.82 million, compared to the average estimate of $62.20 million, marking a 36.7% year-over-year increase [4] - Revenue from Products was $11.37 million, surpassing the average estimate of $10.83 million, reflecting a 23% year-over-year increase [4] Stock Performance - CareDx shares have returned -8.5% over the past month, while the Zacks S&P 500 composite has changed by -2.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Financial Results and Guidance - CareDx, Inc. announced preliminary financial results for Q4 and the year ended December 31, 2024[4]. - The company provided 2025 revenue guidance, details of which are included in the press release[4]. - The financial results and guidance are intended to inform stakeholders and are not deemed "filed" under the Exchange Act[5]. - The company has not disclosed specific financial figures in the provided documents[4]. Corporate Communication - The corporate presentation dated January 13, 2025, is intended to be posted on the company's website[6]. - The press release and corporate presentation are attached as Exhibits 99.1 and 99.2, respectively[9]. - The report was issued on January 13, 2025, indicating the company's commitment to timely communication with investors[12]. Company Information - CareDx, Inc. is registered under the Securities Exchange Act of 1934 and is listed on The Nasdaq Stock Market LLC with the symbol CDNA[2]. - The company is not classified as an emerging growth company under the relevant regulations[3]. - The report was signed by John W. Hanna, President and CEO of CareDx, Inc.[13].

Core Insights - CareDx (CDNA) shares increased by 11.2% to $24.91, following a significant trading volume, contrasting with a 5.2% decline over the past month [1] - The upcoming fourth-quarter 2024 financial results are anticipated to show approximately 30% year-over-year revenue growth, with testing services volume increasing by 14% [2] - The consensus EPS estimate for the quarter is $0.07, reflecting a year-over-year increase of 141.2%, with expected revenues of $85.5 million, up 30.4% from the previous year [3] Earnings and Revenue Expectations - Adjusted EBITDA is projected to be between $25 million and $26 million for the fourth quarter [2] - The consensus EPS estimate has been revised 13.2% higher in the last 30 days, indicating a positive trend that typically leads to price appreciation [4] Industry Context - CareDx is part of the Zacks Medical Services industry, which includes other companies like LifeMD, Inc. (LFMD), that saw a 5.5% increase in its last trading session [4] - LifeMD's EPS estimate remains unchanged at -$0.06, representing a 50% year-over-year change [5]

Group 1 - CareDx (CDNA) closed at $23.10, with a 1.7% gain over the past four weeks, and a mean price target of $32.86 indicating a 42.3% upside potential [1] - The average price targets range from a low of $24 to a high of $40, with a standard deviation of $6.39, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, with a 21.9% increase in the Zacks Consensus Estimate for the current year [10][11] Group 2 - The consensus price target is often questioned for its reliability, as empirical research indicates that it rarely predicts actual stock price movements [5][6] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction [7] - CDNA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11][12]

Company Overview - CareDx (CDNA) is a notable stock within the Medical group, which consists of 1010 companies and currently ranks 3 in the Zacks Sector Rank [2] - CareDx has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook with a 36.9% increase in the consensus estimate for full-year earnings over the past quarter [3] Performance Comparison - Year-to-date, CareDx has returned approximately 6.7%, significantly outperforming the Medical sector's average return of -0.6% [4] - In comparison, DaVita HealthCare (DVA) has also outperformed the sector with a year-to-date return of 15.8% [4] Industry Context - CareDx operates within the Medical Services industry, which includes 59 companies and currently ranks 151 in the Zacks Industry Rank; this industry has seen an average loss of 6.7% this year, highlighting CareDx's superior performance [5] - DaVita HealthCare belongs to the Medical - Outpatient and Home Healthcare industry, which consists of 18 stocks and is ranked 69, with a year-to-date increase of 16.9% [6]

Core Insights - CareDx (CDNA) shares increased by 6.1% to close at $25.07, attributed to higher trading volume compared to typical sessions, with a 3.4% gain over the past four weeks [1] Financial Performance - CareDx is expected to report preliminary fourth-quarter 2024 revenues between $85 million and $86 million, reflecting a 30% year-over-year increase, surpassing the Zacks Consensus Estimate of 25.2% growth [2] - Testing service revenue is projected to rise nearly 35% year-over-year, driven by a 14% increase in volumes [2] - The company anticipates quarterly earnings of $0.07 per share, representing a year-over-year increase of 141.2%, with revenues expected to reach $82.12 million, up 25.2% from the previous year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for CareDx has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - CareDx currently holds a Zacks Rank of 3 (Hold), while another company in the medical services industry, Avantor, Inc. (AVTR), has a Zacks Rank of 4 (Sell) [4]

Group 1 - The article discusses the process of identifying potential investment opportunities for the "Bioreactor" growth portfolio within the Compounding Healthcare Investing Group [1] - The focus is on innovative companies that are developing breakthrough therapies and pharmaceuticals, particularly those with catalysts for potential acquisitions [3] - The investing group offers several model healthcare portfolios, a weekly newsletter, a daily watchlist, and a platform for dialogue and questions among members [4] Group 2 - The author has a beneficial long position in the shares of TMO and BIO, indicating a personal investment interest in these companies [1] - The article encourages readers to explore the subscription marketplace service, Compounding Healthcare, for more insights into investment methods and opportunities [2]